These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 37943964

  • 1. Intra-individual comparison of prostate-specific membrane antigen positron emission tomography/computed tomography versus bone scan in detecting skeletal metastasis at prostate cancer diagnosis.
    Shanmugasundaram R, Saad J, Heyworth A, Wong V, Pelecanos A, Arianayagam M, Canagasingham B, Ferguson R, Goolam AS, Khadra M, Kam J, Ko R, McCombie S, Varol C, Winter M, Mansberg R, Nguyen D, Bui C, Loh H, Le K, Roberts MJ.
    BJU Int; 2024 Feb; 133 Suppl 3():25-32. PubMed ID: 37943964
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Feb; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. A prospective intra-individual comparison of [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-NODAGAZOL PET/CT, and [99mTc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases.
    Lawal IO, Mokoala KMG, Mahapane J, Kleyhans J, Meckel M, Vorster M, Ebenhan T, Rösch F, Sathekge MM.
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):134-142. PubMed ID: 32424485
    [Abstract] [Full Text] [Related]

  • 4. A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE).
    Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, Rinta-Kiikka I, Schildt J, Saukko E, Rautio P, Timonen KL, Matikainen T, Noponen T, Saunavaara J, Löyttyniemi E, Taimen P, Kemppainen J, Dean PB, Blanco Sequeiros R, Aronen HJ, Seppänen M, Boström PJ.
    Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
    [Abstract] [Full Text] [Related]

  • 5. Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer.
    Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, Yaxley AJ, Gianduzzo T, Kua B, McEwan L, Wong D.
    BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
    [Abstract] [Full Text] [Related]

  • 6. Incremental Impact of [68 Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI.
    Szigeti F, Schweighofer-Zwink G, Meissnitzer M, Hauser-Kronberger C, Hitzl W, Kunit T, Forstner R, Pirich C, Beheshti M.
    Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
    [Abstract] [Full Text] [Related]

  • 7. How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography / computed tomography (68Ga-PSMA PET/CT) on primary lymph node staging before radical prostatectomy in intermediate and high risk prostate cancer? A study of patient- and lymph node- based analyses.
    Erdem S, Simsek DH, Degirmenci E, Aydin R, Bagbudar S, Ozluk Y, Sanli Y, Sanli O, Ozcan F.
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [Abstract] [Full Text] [Related]

  • 8. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience.
    Ekmekcioglu O, Yavuzsan AH, Arican P, Kirecci SL.
    J Cancer Res Ther; 2021 Jan; 17(6):1351-1357. PubMed ID: 34916365
    [Abstract] [Full Text] [Related]

  • 9. Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.
    Ma TM, Gafita A, Shabsovich D, Juarez J, Grogan TR, Thin P, Armstrong W, Sonni I, Nguyen K, Lok V, Reiter RE, Rettig MB, Steinberg ML, Kupelian PA, Yang DD, Muralidhar V, Chu C, Feng F, Savjani R, Deng J, Parikh NR, Nickols NG, Elashoff D, Czernin J, Calais J, Kishan AU.
    Eur Urol Oncol; 2022 Feb; 5(1):100-103. PubMed ID: 33602654
    [Abstract] [Full Text] [Related]

  • 10. Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia.
    Song R, Jeet V, Sharma R, Hoyle M, Parkinson B.
    Pharmacoeconomics; 2022 Aug; 40(8):807-821. PubMed ID: 35761117
    [Abstract] [Full Text] [Related]

  • 11. Primary lymph-node staging with 68Ga-PSMA PET in high-risk prostate cancer: pathologic correlation with extended pelvic lymphadenectomy specimens.
    Corona-Montes VE, González-Cuenca E, Fernández-Noyola G, Olarte-Casas MA, Bobadilla-Salazar D, Medrano-Urtecho HM, Asimakopoulos AD.
    Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [Abstract] [Full Text] [Related]

  • 12. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
    Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, Fendler WP, Eiber M, Czernin J, Reiter RE, Calais J.
    Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
    [Abstract] [Full Text] [Related]

  • 13. [68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer.
    Hirmas N, Al-Ibraheem A, Herrmann K, Alsharif A, Muhsin H, Khader J, Al-Daghmin A, Salah S.
    Mol Imaging Biol; 2019 Jun; 21(3):574-581. PubMed ID: 30215174
    [Abstract] [Full Text] [Related]

  • 14. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RA, Bailey DL, Budd R, Hicks RJ, Francis RJ, Lawrentschuk N.
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [Abstract] [Full Text] [Related]

  • 15. 68Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer.
    Klingenberg S, Jochumsen MR, Ulhøi BP, Fredsøe J, Sørensen KD, Borre M, Bouchelouche K.
    J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
    [Abstract] [Full Text] [Related]

  • 16. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB, van Leeuwen PJ, Busstra MB, Brabander T, van der Poel HG, Donswijk ML, Vis AN, Emmett L, Stricker PD, Roobol MJ.
    BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
    [Abstract] [Full Text] [Related]

  • 17. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
    Ergül N, Yilmaz Güneş B, Yücetaş U, Toktaş MG, Çermik TF.
    Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
    [Abstract] [Full Text] [Related]

  • 18. Impact of uptake time on image quality of [68 Ga]Ga-PSMA-11 PET/CT.
    van der Sar ECA, Viol SLM, Braat AJAT, van Rooij R, Lam MGEH, de Jong HWAM, de Keizer B.
    Med Phys; 2023 Dec; 50(12):7619-7628. PubMed ID: 37093883
    [Abstract] [Full Text] [Related]

  • 19. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
    Maestroni UV, Campobasso D, Guarino G, Acampora A, Scarlattei M, Ziglioli F, Dinale F, Baldari G, Migliari S, Gasparro D, Ferretti S, Silini EM, Ruffini L.
    Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
    [Abstract] [Full Text] [Related]

  • 20. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis.
    Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y, Tay KJ, Tuan J, Thang SP, Lam W, Yuen J, Lawrentschuk N, Hofman MS, Murphy DG, Chen K.
    Eur Urol; 2023 Jul; 84(1):36-48. PubMed ID: 37032189
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.